A5079427446- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Colorectal and Anal Carcinomas
- Cancer, Hypoxia, and Metabolism
- Brain Metastases and Treatment
- Lung Cancer Diagnosis and Treatment
- Ear and Head Tumors
- Oral and Maxillofacial Pathology
- Metabolism, Diabetes, and Cancer
- CAR-T cell therapy research
- Head and Neck Surgical Oncology
- Photodynamic Therapy Research Studies
- Immunotherapy and Immune Responses
- Cancer-related Molecular Pathways
- Immune cells in cancer
- Tumors and Oncological Cases
- Multiple and Secondary Primary Cancers
- Advanced Radiotherapy Techniques
- Cholangiocarcinoma and Gallbladder Cancer Studies
Sidney Kimmel Cancer Center
2016-2025
Thomas Jefferson University Hospital
2014-2025
Thomas Jefferson University
2015-2024
Sidney Kimmel Comprehensive Cancer Center
2024
Jefferson University Hospitals
2020-2024
Icahn School of Medicine at Mount Sinai
2024
Temple College
2022
Temple University
2022
Portland State University
2021
The University of Texas MD Anderson Cancer Center
2020
Abstract Background Recurrent head and neck squamous cell carcinoma (rHNSCC) represents a significant global health burden with an unmet medical need. In this study we determined the safety efficacy of RM‐1929 photoimmunotherapy in patients heavily pretreated rHNSCC. Methods (anti‐EGFR–IR700 dye conjugate) was infused, followed by tumor illumination. We evaluated safety, response, pharmacokinetics. Results Nine were enrolled Part 1 (dose‐finding) 30 2 (safety efficacy). No dose‐limiting...
Cervical metastasis is the most important prognostic factor in head and neck cancer patients. The significance of extracapsular spread tumor metastatic lymph nodes has also been documented. presence further reduces survival by 50% those patients with cervical disease. Most clinically negative necks (stage N0) have a good prognosis. However, some these will disease distant eventually die. Because predictor poor outcome, we hypothesized that may be subset who outcomes. One hundred nine had...
Relapsed/metastatic salivary gland carcinomas (SGCs) have a wide diversity of histologic subtypes associated with variable clinical aggressiveness and response to local systemic therapies. We queried whether comprehensive genomic profiling could define the tumor uncover clinically relevant alterations, revealing new routes targeted therapies for patients relapsed metastatic disease.From series 85 686 cases, DNA was extracted from 40 µm formalin-fixed paraffin embedded (FFPE) sections 623...
<h3>Importance</h3> Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment and are now standard of care. Although sex is associated with immune function immune-related diseases, the interaction between ICIs understudied. <h3>Objective</h3> To examine whether cancer immunotherapy effectiveness varies female male patients advanced treated either nivolumab plus ipilimumab combination therapy or anti–programmed cell death protein 1 (PD-1) (namely, pembrolizumab nivolumab)....
Abstract Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome patients associated with greater costs health systems. We evaluated the utilization of supportive their relationship myeloprotective agent, trilaciclib. Methods Data were pooled from three independent randomized phase 2 clinical...
Larotrectinib is a first-in-class, highly selective, and central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of adult pediatric patients with TRK fusion cancer. We report efficacy safety larotrectinib in fusion-positive salivary gland cancers.
Introduction: Monocarboxylate transporter 1 (MCT1) is an importer of monocarboxylates such as lactate and pyruvate a marker mitochondrial metabolism. MCT1 highly expressed in subgroup cancer cells to allow for catabolite uptake from the tumor microenvironment support We studied protein expression broad group breast invasive ductal carcinoma specimens determine its association with subtypes outcomes. Methods: was evaluated by immunohistochemistry on tissue micro-arrays (TMA) obtained through...
Abstract Purpose: We hypothesize that the addition of phosphodiesterase-5 inhibitor tadalafil to PD-1 nivolumab, is safe and will augment immune-mediated antitumor responses in previously untreated squamous cell carcinoma head neck (HNSCC). Patients Methods: conducted a two-arm multi-institutional neoadjuvant randomized trial any-stage resectable HNSCC (NCT03238365). were stratified at randomization by human papillomavirus (HPV) status. both arms received nivolumab 240 mg intravenously on...
Background Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’ tumor associated antigen due to its expression in vast number of cancers. We evaluated plasmid DNA-encoded hTERT an immunotherapy across nine cancer types. Methods A phase 1 clinical trial was conducted adult patients with no evidence disease following definitive surgery and standard therapy, who were at high risk relapse. Plasmid DNA encoding one two variants (INO-1400 or INO-1401) without...
PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of neoadjuvant randomized window-of-opportunity trial nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated effects vary by site involvement (primary tumor, lymph nodes) determine how radiographic tumor shrinkage correlates pathologic effect. Forty-four enrolled NCT03238365 were treated 240 mg intravenously on days 1 15 or without oral...
<p>Supplementary Appendix</p>
<p>Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: primary site, stratifed by arm. C: RECIST tumor site (yellow) and nodes (purple), arm.</p>
<div>AbstractPurpose:<p>We evaluated whether indoleamine 2,3-dioxygenase (IDO1) inhibitor (IDOi) BMS986205 + PD-1 nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable head neck squamous cell carcinoma (HNSCC). We employed response-adaptive surgical timing to identify responders immunotherapy enhance their response.</p>Patients Methods:<p>Patients with HNSCC were 3:1 randomized receive or without orally daily...